Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan notifications and does not contain consolidated financial statements or performance metrics.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details specific increases in notional interests in Ordinary Shares and American Depositary Shares (ADSs) for connected persons following the notional re-investment of dividends paid on October 3, 2013.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It strictly reports on the administrative notification of share plan adjustments in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Important Facts for Investors
- Transaction Type: Notification of increases in notional interests in the 2009 Performance Share Plan.
- Valuation: Transactions occurred at a price of 1571 pence per Ordinary Share and $50.84 per ADS.
- Participants: Dr M M Slaoui (41,965 ADSs) and Mr P C Thomson (72,215 Ordinary Shares) are the connected persons listed.
- Payout Terms: Notional dividends will be paid out based on the percentage of holdings that vest after the relevant measurement period.
- Timing: The notification was issued on October 8, 2013, and the filing was signed on October 9, 2013.